GPR40ant39 |
GPR40ant39 : (Predicted) allosteric antagonist of FFAR1
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| FFAR1 |
|
|
Antagonist
16 nM - 1.6 uM
Selectivity
In Vitro Selectivity Assessment
Potency: IC50 - Na+/K+ ATPase (pig): 790 nM
Potency Assay Off-Target:
The compound had no activity in CEREP panel, including 144 GPCRs, at 1 uM. The above is the only tar ...
Selectivity Assessment Description:
hERG pIC50=5.0
Potency Cellular
In Vitro
FFAR1
Mode of Action: Antagonist
Structure-Activity-Relationship data available? No
In Vivo Validations
male Zucker fa/fa rat
Dose: 80 mg/kg
Route of delivery:
Oral
Plasma half life:
69 min
Systemic clearance:
30 mL/min/kg
Target engagement assay:
Indirect. In beta-3 agonist challenge assays (lipolysis), GPR40ant39 inhibited nonesterified fatty acid (NEFA)-driven insulin resistance.
Reference: --
Chemical Information
| Molecular Formula | C21H16F3N5O |
| SMILEs | CC1(C#N)CN(c2cc(COc3ccc(F)c(F)c3F)nc(-c3ccccn3)n2)C1 |
| InChI | InChI=1S/C21H16F3N5O/c1-21(10-25)11-29(12-21)17-8-13(27-20(28-17)15-4-2-3-7-26-15)9-30-16-6-5-14(22)18(23)19(16)24/h2-8H,9,11-12H2,1H3 |
| Molecular weight | 411.13 Da |
| AlogP | 3.8847800000000037 |
| HBond acceptors | 6 |
| HBond donors | -- |
| Atoms | 46 |
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the portal.